HUE062092T2 - Neuropátiás fájdalom kezelésére szolgáló, alacsony koncentrációjú FLT-receptorgátló - Google Patents

Neuropátiás fájdalom kezelésére szolgáló, alacsony koncentrációjú FLT-receptorgátló

Info

Publication number
HUE062092T2
HUE062092T2 HUE17727913A HUE17727913A HUE062092T2 HU E062092 T2 HUE062092 T2 HU E062092T2 HU E17727913 A HUE17727913 A HU E17727913A HU E17727913 A HUE17727913 A HU E17727913A HU E062092 T2 HUE062092 T2 HU E062092T2
Authority
HU
Hungary
Prior art keywords
treatment
neuropathic pain
low dosage
receptor inhibitor
flt3 receptor
Prior art date
Application number
HUE17727913A
Other languages
English (en)
Hungarian (hu)
Inventor
Jean Valmier
Original Assignee
Inst Nat Sante Rech Med
Univ Montpellier
Biodol Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Montpellier, Biodol Therapeutics filed Critical Inst Nat Sante Rech Med
Publication of HUE062092T2 publication Critical patent/HUE062092T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE17727913A 2016-06-08 2017-06-08 Neuropátiás fájdalom kezelésére szolgáló, alacsony koncentrációjú FLT-receptorgátló HUE062092T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305669.0A EP3254698A1 (en) 2016-06-08 2016-06-08 Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
HUE062092T2 true HUE062092T2 (hu) 2023-09-28

Family

ID=56134285

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17727913A HUE062092T2 (hu) 2016-06-08 2017-06-08 Neuropátiás fájdalom kezelésére szolgáló, alacsony koncentrációjú FLT-receptorgátló

Country Status (5)

Country Link
US (1) US10709687B2 (enExample)
EP (2) EP3254698A1 (enExample)
JP (1) JP7134097B2 (enExample)
HU (1) HUE062092T2 (enExample)
WO (1) WO2017211937A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3955920A1 (en) * 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
KR102231446B1 (ko) * 2021-01-21 2021-03-24 (주) 와이디생명과학 베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물
AU2022426699A1 (en) 2021-12-30 2024-07-11 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424689A1 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
CA2462657C (en) 2001-10-30 2011-04-26 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
BR0215360A (pt) 2001-12-27 2004-12-14 Theravance Inc Derivados de indolina úteis como inibidores de proteìna quinase
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
KR20050042478A (ko) 2002-08-14 2005-05-09 버텍스 파마슈티칼스 인코포레이티드 프로테인 키나아제 억제제 및 이의 용도
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
JPWO2004039782A1 (ja) 2002-10-29 2006-03-02 麒麟麦酒株式会社 Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
WO2004043389A2 (en) 2002-11-13 2004-05-27 Chiron Corporation Methods of treating cancer and related methods
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
ATE425160T1 (de) 2002-12-18 2009-03-15 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
JP2009511628A (ja) 2005-10-18 2009-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｌｔ３キナーゼの阻害方法
BRPI0708823B1 (pt) 2006-03-17 2022-01-18 Ambit Biosciences Corporation Composto, e, composição
WO2009061446A1 (en) 2007-11-08 2009-05-14 Ambit Biosciences Corp. Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
SI2252597T1 (sl) 2008-02-01 2014-07-31 Akinion Pharmaceuticals Ab Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze
EP2521782B1 (en) 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists for the treatment or the prevention of pain disorders
EP3174859B1 (en) * 2014-07-31 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists

Also Published As

Publication number Publication date
US20190298691A1 (en) 2019-10-03
EP3468602A1 (en) 2019-04-17
EP3254698A1 (en) 2017-12-13
US10709687B2 (en) 2020-07-14
WO2017211937A1 (en) 2017-12-14
JP2019517536A (ja) 2019-06-24
JP7134097B2 (ja) 2022-09-09
EP3468602B1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
EP3180009A4 (en) Zoledronic acid dosage forms for the treatment of pain
IL253945B (en) kdm1a inhibitors to treat the disease
IL262159A (en) Equipment for implanting medical devices
IL270752B (en) Pyrrolopyridine-aniline compounds for the treatment of skin disorders
IL276482A (en) Compounds for pain management
PL3424499T3 (pl) Kompozycja farmaceutyczna do leczenia bólu neuropatycznego
ZA201705847B (en) Treatment of pain
PT3180434T (pt) Chamarizes oligonucleotídicos para o tratamento da dor
GB201506654D0 (en) Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia
HUE062092T2 (hu) Neuropátiás fájdalom kezelésére szolgáló, alacsony koncentrációjú FLT-receptorgátló
IL266243A (en) Use of senicapoc for the treatment of neuropathic pain
ZA201804588B (en) Pharmaceutical formulations for the treatment of diabetes
IL258316A (en) A combination of trazodone and gabapentin for the treatment of pain
IL273364A (en) MPGES-1 inhibitor for the treatment of osteoarthritis pain
PL3178521T3 (pl) Urządzenie do leczenia zintegrowanego rytmu serca
PL3638223T3 (pl) Bromheksyna w leczeniu bólu
GB201714772D0 (en) Dosage forms of therapeutic compounds
GB201714241D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
HK40002410A (en) Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain
AU2016900635A0 (en) Inhibitors of beta-arrestin-Neurokinin 1 Receptor Interactions for the Treatment of Pain
GB201701928D0 (en) Compounds for the treatment of hyperglycaemia
PT3185855T (pt) Comprimido revestido por película para o tratamento da dor aguda
GB201603752D0 (en) Treatment of hypothyroidism
GB201603755D0 (en) Treatment of hypothyroidism
GB201504688D0 (en) Treatment for pain